Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-282494

PROSPECTUS SUPPLEMENT

(To Prospectus Dated October 10, 2024)

<div align='center'>Up to $50,000,000

Shares of Common Stock</div>

We have entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), relating to the sale of shares of our common stock, par value $0.001 per share (“common stock”) offered by this prospectus. In accordance with the terms of such Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000from time to time through Leerink Partners acting as our sales agent.

Our common stock is listed on The NASDAQ Capital Market under the symbol “CRVO.” On May 9, 2025, the last reported sale price of our common stock was $8.49 per share.

Sales of our common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Leerink Partners is not required to sell any specific amount of securities, but will act as sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Leerink Partners and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to Leerink Partners for sales of our common stock sold pursuant to the Sales Agreement will be 3.0% of the aggregate gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Leerink Partners will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Investing in our common stock involves a high degree of risk. We strongly recommend that you carefully read the risks we describe in this prospectus supplement, as well as the risk factors that are incorporated by reference into this